Literature DB >> 24012693

Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.

Hui Pang1, Hailing Lu, Hongtao Song, Qingwei Meng, Yanbin Zhao, Na Liu, Fei Lan, Ying Liu, Suhong Yan, Xiaoqun Dong, Li Cai.   

Abstract

OBJECTIVE: To determine the correlation of cell adhesion molecules (osteopontin-c, E-cadherin and β-catenin) with clinicopathological characteristics in breast cancer.
METHODS: Immunostaining of osteopontin-c, E-cadherin and β-catenin were conducted in 170 samples of breast cancer and 30 samples of adjacent normal breast tissues. The correlation of osteopontin-c, E-cadherin and β-catenin expression level with clinicopathological characteristics was evaluated by Pearson's chi-square and Wilcoxon rank-sum test. Univariate and multivariate Cox hazard regression model was used to assess the prognostic values of osteopontin-c, E-cadherin and β-catenin in clinical outcome of breast cancer.
RESULTS: A higher level of osteopontin-c whereas lower levels of E-cadherin and β-catenin were observed in breast cancer as compared with the normal breast tissues. The expression of osteopontin-c was negatively associated with the expression of E-cadherin and β-catenin. The expression of osteopontin-c correlated with lymph node metastasis, and advanced TNM stage and histologic grade. The expression of E-cadherin correlated with low histologic grade; and β-catenin with low TNM stage and histological grade. Moreover, high osteopontin-c level correlated with tumor recurrence or metastasis as well as triple negative subtype. The expression of osteopontin-c was an independent prognostic factor for both disease-free and overall survival of breast cancer patients.
CONCLUSION: The data suggest that the expression of osteopontin-c could serve as a prognostic factor of breast cancer.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; CAMs; DFS; E-cadherin; ER; HER-2/neu; OPN; OS; Osteopontin-c; PR; Survival; cell adhesion molecules; disease-free survival; estrogen receptor; human epidermal growth factor receptor 2; osteopontin; overall survival; pN; positive lymph node; progesterone receptor; β-Catenin

Mesh:

Substances:

Year:  2013        PMID: 24012693     DOI: 10.1016/j.canep.2013.08.005

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  24 in total

Review 1.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

Review 2.  Prognostic significance of osteopontin in patients with lung cancer: a meta-analysis.

Authors:  Bin Peng; Yi-Han Wang; Zhuo Huang; Shi-Jian Feng; Yong-Sheng Wang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

3.  Current status of the prognostic molecular biomarkers in breast cancer: A systematic review.

Authors:  Goro Kutomi; Toru Mizuguchi; Fukino Satomi; Hideki Maeda; Hiroaki Shima; Yasutoshi Kimura; Koichi Hirata
Journal:  Oncol Lett       Date:  2017-01-17       Impact factor: 2.967

Review 4.  Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer.

Authors:  Ayesha Khalid; Joy Wolfram; Ilaria Ferrari; Chaofeng Mu; Junhua Mai; Zhizhou Yang; Yuliang Zhao; Mauro Ferrari; Xiaojing Ma; Haifa Shen
Journal:  Mini Rev Med Chem       Date:  2015       Impact factor: 3.862

5.  Prognostic value of osteopontin expression in breast cancer: A meta-analysis.

Authors:  Ying-Yi Xu; Ya-Ya Zhang; Wei-Feng Lu; Yan-Jun Mi; Yu-Qiang Chen
Journal:  Mol Clin Oncol       Date:  2014-12-22

6.  Amygdalin-mediated inhibition of non-small cell lung cancer cell invasion in vitro.

Authors:  Liyu Qian; Bo Xie; Yaguo Wang; Jun Qian
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

7.  Overexpression of osteopontin promotes cell proliferation and migration in human nasopharyngeal carcinoma and is associated with poor prognosis.

Authors:  Haimei Qin; Rong Wang; Guijiang Wei; Huaifei Wang; Guogang Pan; Rentong Hu; Yesheng Wei; Renguang Tang; Junli Wang
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-12-06       Impact factor: 2.503

8.  Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer.

Authors:  C E Weber; A N Kothari; P Y Wai; N Y Li; J Driver; M A C Zapf; C A Franzen; G N Gupta; C Osipo; A Zlobin; W K Syn; J Zhang; P C Kuo; Z Mi
Journal:  Oncogene       Date:  2014-12-22       Impact factor: 9.867

9.  E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors.

Authors:  Eike Burandt; Felix Lübbersmeyer; Natalia Gorbokon; Franziska Büscheck; Andreas M Luebke; Anne Menz; Martina Kluth; Claudia Hube-Magg; Andrea Hinsch; Doris Höflmayer; Sören Weidemann; Christoph Fraune; Katharina Möller; Frank Jacobsen; Patrick Lebok; Till Sebastian Clauditz; Guido Sauter; Ronald Simon; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Sarah Minner; Rainer Krech; David Dum; Till Krech; Andreas Holger Marx; Christian Bernreuther
Journal:  Biomark Res       Date:  2021-06-05

10.  Osteopontin isoform c promotes the survival of cisplatin-treated NSCLC cells involving NFATc2-mediated suppression on calcium-induced ROS levels.

Authors:  Jing Huang; Mu Hu; Huan Niu; Jing Wang; Yang Si; Shan Cheng; Wei Ding
Journal:  BMC Cancer       Date:  2021-06-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.